Abstract

The present invention provides a composition that contains γ-aminobutyric acid (GABA) as an active ingredient and is used for ameliorating or preventing confusion and/or bewilderment in a subject. The composition according to the present invention is preferably capable of ameliorating or preventing confusion and/or bewilderment evaluated by Profile of Mood States 2nd Edition (POMS2).

IPC Classes  ?

• A23L 33/175 - Amino acids
• A23L 2/52 - Adding ingredients
• A61K 9/08 - Solutions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants

Abstract

The present invention provides a method for producing a GABA-containing powder using a lactic acid bacterium, which enables the production of a GABA product having improved taste and/or odor. Specifically, the present invention provides a method for producing a γ-aminobutyric acid (GABA)-containing powder, the method comprising: (1) a fermentation step in which a lactic acid bacterium having GABA production capability is inoculated into a raw material and cultured to obtain a GAVA-containing fermented liquid; (2) a pH adjustment step in which the pH of the fermented liquid is adjusted to obtain a pH-adjusted fermented liquid; (3) a step in which the pH-adjusted fermented liquid is heated to obtain a heat-sterilized fermented liquid in which the lactic acid bacterium is sterilized; and (4) a step in which the heat-sterilized fermented liquid is treated with activated carbon.

IPC Classes  ?

• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• A23L 33/175 - Amino acids
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Provided is a novel composition or method for inhibiting fibrosis. This composition for inhibiting fibrosis comprises an antibody that specifically binds to PAD2 and is used. In addition, a pharmaceutical composition for treating fibrotic disease comprises an antibody that specifically binds to PAD2 and a pharmaceutically acceptable carrier, and may be used. Further, a kit for inhibiting fibrosis comprises an antibody that specifically binds to PAD2 and may be used.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

According to the present invention, a composition that induces the feeling of satiety or suppresses binge eating is provided. According to the present invention, a composition that induces the feeling of satiety or suppresses binge eating is provided. The present invention provides a GABA-containing composition for inducing transient satiety in a subject. The present invention also provides a GABA-containing composition for suppressing binge eating on a fasting condition in a subject.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention provides: a method for dissolving a sparingly water-soluble protein; and a molded article made from a protein solution obtained by the method. The present invention provides: a method for dissolving a sparingly water-soluble protein, the method comprising a step for mixing together a hydroxyl group-containing polymer, a sparingly water-soluble protein, and an ionic liquid. Furthermore, the present invention makes it possible to produce a molded body from a sparingly water-soluble protein solution obtained by such method.

IPC Classes  ?

• C08L 89/04 - Products derived from waste materials, e.g. horn, hoof or hair
• C08K 5/19 - Quaternary ammonium compounds
• C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
• C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08L 31/04 - Homopolymers or copolymers of vinyl acetate

Abstract

The present invention provides a composition for inducing a flow (zone) state in a subject, the composition containing γ-aminobutyric acid (GABA). The composition according to the present invention is capable of inducing a subject, who is engaged in a specific operation or movement, into a flow (zone) state.

IPC Classes  ?

• A23L 33/175 - Amino acids
• A61K 9/08 - Solutions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 25/26 - Psychostimulants, e.g. nicotine, cocaine

Abstract

According to the present invention, GABA can be used in fields other than food.　The present invention provides a plant growth-promoting composition containing GABA. By applying the GABA-containing composition according to the present invention to plants, a plant growth-promoting effect can be expected.

IPC Classes  ?

• A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
• A01G 7/06 - Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
• A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
• A01P 21/00 - Plant growth regulators

Abstract

Provided is an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1, HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, HCDR3 comprises an amino acid sequence of SEQ ID NO: 3, LCDR1 comprises an amino acid sequence of SEQ ID NO: 4, LCDR2 comprises an amino acid sequence of SEQ TD NO: 5, and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Provided is a novel antibody which may be used for the treatment of SARS-CoV-2.　An antibody or an antigen-binding fragment thereof according to the present disclosure is an anti-CADM1 antibody or an antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of (Ca) and (Cb): (Ca) an antibody comprising the amino acid sequences of a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 represented by SEQ ID NOs:1, 2 and 3, respectively, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 represented by SEQ ID NOs:4, 5 and 6, respectively; and (Cb) a variant of (a) antibody including some of substitution, insertion, addition, or deletion in the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and/or the light chain CDR3.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides a method for dissolving a sparingly water-soluble protein and a method for producing a polymer molded body that contains a sparingly water-soluble protein.　The present invention provides a method for dissolving a sparingly water-soluble protein, the method including a step for combining the sparingly water-soluble protein and a water-soluble tertiary amine oxide. The present invention also makes it possible to produce a molded body from a protein solution obtained by such a method.

IPC Classes  ?

• C08J 3/205 - Compounding polymers with additives, e.g. colouring in the presence of a liquid phase
• C08J 3/02 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
• C08K 5/32 - Compounds containing nitrogen bound to oxygen
• C08K 5/357 - Six-membered rings
• C08L 1/02 - CelluloseModified cellulose
• C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof

Abstract

Provided are a novel composition and method for inhibiting fibrosis. A composition for inhibiting fibrosis containing an antibody that specifically binds to PAD2 is used. Alternatively, a pharmaceutical composition for treating fibrosis containing an antibody that specifically binds to PAD2 and a pharmaceutically acceptable carrier may be used. Alternatively, a kit for inhibiting fibrosis containing an antibody that specifically binds to PAD2 may be used.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/13 - Immunoglobulins

Abstract

The present invention relates to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A23L 33/12 - Fatty acids or derivatives thereof
• A61P 3/06 - Antihyperlipidemics
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

According to the present invention, provided is a composition for inducing satiety or suppressing overeating.　This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provides a GABA-containing composition for suppressing overeating in a subject when the subject is hungry.

IPC Classes  ?

• A23L 33/175 - Amino acids
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/06 - Antimigraine agents
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides highly safe functional fibers by imparting a novel function to recycled cellulose fibers.　The present invention provides recycled cellulose fibers which contain an eggshell membrane hydrolysate. The recycled cellulose fibers according to the present invention may contain about 0.5 part by mass to about 25 parts by mass of the eggshell membrane hydrolysate per about 100 parts by mass of cellulose.

IPC Classes  ?

• D01F 2/10 - Addition to the spinning solution or spinning bath of substances which exert their effect equally well in either
• D01D 5/06 - Wet spinning methods

Abstract

−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided is a novel composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing γ-aminobutyric acid.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A23L 33/175 - Amino acids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided is a composition containing a ceramide derived from a natural substance.　The present invention provides a composition containing a polyphenol and a ceramide. The invention of the present application further provides a composition containing a ceramide derived from wine fermentation lees. Also provided is a method for producing a ceramide-containing composition, the method comprising a step for washing wine fermentation lees and a step for extracting the resulting washing residue using a polar solvent.

IPC Classes  ?

• A61K 8/42 - Amides
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A61K 8/34 - Alcohols
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 31/05 - Phenols
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 17/18 - Antioxidants, e.g. antiradicals
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations

Abstract

The present invention addresses the problem of providing a novel method for producing a γ-aminobutyric acid (GABA) powder and a product that contains a GABA powder produced by the production method. The present invention provides a method for producing a GABA-containing powder, said production method comprising: (1) a fermentation step for inoculating a lactic acid bacterium capable of producing GABA into a starting material and culturing to give a GABA-containing fermented liquid; (2) a heat sterilization step for heating the fermented liquid to sterilize the lactic acid bacterium; (3) a step for adding an excipient to the fermented liquid; (4) a heating and mixing step for mixing the fermented liquid, which contains the excipient added thereto, under heating to give a liquid mixture; (5) a standing step for allowing the liquid mixture to stand still; and (6) a spray-drying step for spray-drying the liquid mixture to give the GABA-containing powder.

IPC Classes  ?

• C12P 13/02 - Amides, e.g. chloramphenicol
• A23L 33/175 - Amino acids
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61P 17/00 - Drugs for dermatological disorders
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention provides a whitening agent which is highly safe and also has an excellent whitening effect.　The present invention provides a skin whitening composition containing trehalose as an active ingredient. The present invention also provides a method for improving the brightness of the skin, the method comprising a step for applying a skin whitening composition containing trehalose as an active ingredient.

IPC Classes  ?

• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 8/60 - SugarsDerivatives thereof
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61P 17/00 - Drugs for dermatological disorders
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid sequence of SEQ ID NO: 4, LCDR2 includes an amino acid sequence of SEQ ID NO: 5, and LCDR3 includes an amino acid sequence of SEQ ID NO: 6, or an antibody fragment thereof.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present invention provides a composition characterized by containing two or more selected from the group consisting of Bifidobacteria or culture solutions thereof, glutamic acid, or polymers or salts thereof, and rice bran-derived fermented products, as well as an agent for promoting Staphylococcus epidermidis proliferation, suppressing Staphylococcus aureus proliferation or improving bacterial flora, or an agent for preventing or alleviating dandruff, itching or hair loss of a head, the agent containing the composition.

IPC Classes  ?

• A61K 8/9728 - Fungi, e.g. yeasts
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 35/74 - Bacteria
• A61K 35/745 - Bifidobacteria
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 5/00 - Preparations for care of the hair
• A61Q 5/02 - Preparations for cleaning the hair
• A61Q 5/12 - Preparations containing hair conditioners

Abstract

The present invention pertains to a digestive lipase activity inhibitor containing, as an active ingredient, at least one selected from the group consisting of linoleic acid and oleic acid.

IPC Classes  ?

• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A23L 33/12 - Fatty acids or derivatives thereof
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Technical Problem] To provide a novel composition for more efficiently improving endurance than the conventional art. [Solution to Problem] A composition for improving endurance, comprising γ-aminobutyric acid.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A23L 33/17 - Amino acids, peptides or proteins
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Provided is a novel composition for preventing the deterioration in a cognitive function or improving the cognitive function in a subject. A composition for preventing the deterioration in a cognitive function and/or improving the cognitive function in a subject, the composition containing γ-aminobutyric acid.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/175 - Amino acids
• A23L 2/52 - Adding ingredients
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Abstract

Problem to be solved: An object of the present invention is to provide a novel fat absorption inhibiting agent. Solution to the problem: The present invention provides a fat absorption inhibiting agent comprising pulverized defatted sesame seeds or a processed product thereof. The present invention also provides a fat absorption inhibiting agent comprising defatted sesame seeds having a 50th percentile particle size of 1 to 200 μm as determined by laser diffraction/scattering and a compressibility index of 30 to 80%. The fat absorption inhibiting agent of the present invention preferably has lipase inhibitory activity. The present invention also provides a food comprising the agent. The present invention also provides defatted sesame seeds having a 50th percentile particle size of 1 to 200 μm as determined by laser diffraction/scattering and a compressibility index of 30 to 80%. The present invention provides a method for inhibiting obesity in a human or animal, the method comprising administering to a human or animal the agent, the food or the defatted sesame seeds.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 3/04 - AnorexiantsAntiobesity agents
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 25/00 - Food consisting mainly of nutmeat or seedsPreparation or treatment thereof
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

Provided is a novel utilization of the vitelline membrane and chalaza occurring as waste produced in liquid egg production processes. This cosmetic composition is a cosmetic composition for improving the condition of the skin and comprises a poultry-derived vitelline membrane component and/or chalaza component.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/00 - Drugs for dermatological disorders
• A61Q 19/00 - Preparations for care of the skin
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli

Abstract

To obtain an anti-PAD2 antibody having excellent PAD2 inhibitory activity. Provided is an anti-PAD2 antibody that specifically binds to positions 341 to 357 of PAD2. Also provided is an anti-PAD2 antibody that specifically binds to a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Abstract

Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.

IPC Classes  ?

• A61K 38/07 - Tetrapeptides
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 5/00 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof
• C07K 5/04 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing only normal peptide links
• C07K 5/10 - Tetrapeptides
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Provided is an anti-PAD2 antibody which has excellent PAD2 inhibitory activity. The used anti-PAD2 antibody specifically binds to positions 341-357 of PAD2 or specifically binds to a peptide having an amino acid sequence indicated by SEQ ID NO: 1.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/08 - Monoclonal antibodies

Goods & Services

Gamma-aminobutyric acid (GABA) for use as a food additive; Fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive Dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid, and gelled form

Abstract

−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12N 15/09 - Recombinant DNA-technology
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.

IPC Classes  ?

• A61K 38/05 - Dipeptides
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A23C 19/093 - Addition of non-milk fats or non-milk proteins
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
• A23L 2/60 - Sweeteners
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 8/73 - Polysaccharides
• A23L 2/56 - Flavouring or bittering agents
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23C 19/00 - CheeseCheese preparationsMaking thereof
• A23L 2/52 - Adding ingredients
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations

Abstract

A method for predicting the therapeutic effect of a FSTL1 inhibitor in a cancer patient, said method being characterized by comprising the steps of: (1) measuring the expression level of FSTL1 and/or DIP2A in a sample collected from the patient; (2) comparing a measurement value with a reference value; and (3) determining that the therapeutic effect is promised when the measurement value is higher than the reference value. For example, according to the present invention, a companion diagnosis for predicting the efficacy or the like of a treatment with a FSTL1 inhibitor can be performed suitably.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• C12N 15/09 - Recombinant DNA-technology
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A preventative and/or therapeutic agent for osteogenesis imperfecta, osteoporosis and/or osteoarthritis containing a peptide consisting of an amino acid sequence shown by (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) or (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). This agent can be taken orally, has osteogenic function, and has a preventative and/or healing-promoting effect on bone fractures and is therefore very useful in the prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• A61K 38/07 - Tetrapeptides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The present invention provides a hair regrowth promoter comprising an egg-yolk protein hydrolysate as an active ingredient. The egg-yolk protein hydrolysate is a safe ingredient produced from a natural source, and therefore can be widely used in daily consumable products, such as food and drink products, medicaments, animal feeds, and dietary supplements, or as a food additive, etc. The promoter etc. of the present invention can be orally administered and is thus very advantageous.

IPC Classes  ?

• A23L 33/18 - PeptidesProtein hydrolysates
• A23L 27/21 - Synthetic spices, flavouring agents or condiments containing amino acids
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61Q 7/00 - Preparations for affecting hair growth
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO: 1), (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or a derivative thereof or a salt thereof.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• C07K 7/04 - Linear peptides containing only normal peptide links
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A23L 33/18 - PeptidesProtein hydrolysates
• C07K 14/51 - Bone morphogenic factorOsteogeninOsteogenic factorBone-inducing factor
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Acquired are an anti-PAD4 antibody having exceptional characteristics, or an exceptional method for treating RA. An anti-PAD4 antibody is used that binds specifically to an epitope including positions 345, 347, and 348 of PAD4. This anti-PAD4 antibody may inhibit the citrulline activity of PAD4. The KD (M) of this anti-PAD4 antibody may also be 9.0 × 10-9 or less. Alternatively, an anti-PAD4 antibody and a TNFα inhibitor may be used in combination.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/99 - Enzyme inactivation by chemical treatment
• C12P 21/08 - Monoclonal antibodies

Abstract

　The present invention provides an anti-FSTL1 antibody, or a fragment or functional equivalent thereof, said antibody having an- epitope in a site selected from a group consisting of positions 48-100, 148-162, 193-216, 205-228 or 272-289 of the amino acid of SEQ ID NO:1 (human FSTL1 amino acid sequence). Also provided is an agent obtained by combining an FSTL1 suppressor and another anti-cancer agent. The present invention is understood to effectively eliminate immunosuppression, immunodeficiency and other forms of immune breakdown.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 37/04 - Immunostimulants
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

An agent containing a poultry leg or a treatment product thereof, preferably a hydrolysate of an extract of a poultry leg, can promote the production of hyaluronic acid, has an excellent prophylactic or therapeutic effect on joint disorders and also has an effect of improving dryness, wrinkling or tenseness of skin, an effect of moisturizing skin and the like, and is therefore useful as a drug, a quasi drug, a cosmetic, a food or a feed.

IPC Classes  ?

• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 9/20 - Pills, lozenges or tablets
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides a hair growth promoter containing an egg-yolk protein hydrolysate as an effective component thereof. The egg-yolk protein hydrolysate is a naturally-derived, safe, and used widely as a food and beverage item suitable for daily consumption and in pharmaceuticals, animal fodder, supplements, and food additives, etc. In addition, the present invention is particularly useful as a result of being capable of being orally administered.

IPC Classes  ?

• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 7/00 - Preparations for affecting hair growth

Goods & Services

Custom purification of antibodies.

Abstract

　In order to provide an antibody or antibody fragment including the variable region of said antibody for the H5 subtypes of the avian influenza virus, an antigen polypeptide, and uses thereof, the present invention provides: an antibody or antibody fragment including the variable region of said antibody, which specifically binds to the HA1 antigen polypeptide of the HA1 region of the H5 subtypes of the avian influenza virus, said antigen polypeptide comprising the amino acid sequence represented by SEQ ID NO: 10; the HA1 antigen polypeptide comprising the amino acid sequence represented by SEQ ID NO: 10; and uses of the antibody and antibody fragment including the variable region of the antibody.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Goods & Services

Custom purification of antibodies

Abstract

　The present invention provides an agent for the prevention and/or treatment of lung disease containing a compound having (i) a function for suppressing the transformation of epithelial cells into mesenchymal traits in the lung tissue and/or (ii) a function for suppressing enhancement of mesenchymal traits of fibroblasts in the lung tissue to provide a highly safe agent for the prevention and/or treatment of interstitial pneumonia or pulmonary fibrosis having a high therapeutic effect.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

In order to provide a novel peptide that has both an osteogenesis-promoting effect and a chondrocyte proliferation-promoting effect, the present invention provides a peptide or a derivative or salt thereof, wherein the peptide has amino acid sequence (a), (b), or (c), 100 or fewer of amino acid residues, and osteoblast proliferation-promoting activity. (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (sequence No. 1). (b) Amino acid sequence having conservative substitution or deletion of 1 to 3 amino acids in the amino acid sequence (a). (c) Amino acid sequence formed from at least four linked amino acids in the amino acid sequence (a) or (b).

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A23L 1/305 - Amino acids, peptides or proteins 
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides a novel active ingredient which can be safely used in preventing, ameliorating or treating diseases related to the cartilage such as cartilage damages and cartilage disorders. Since the egg yolk protein hydrolyzate has an effect on chondrocyte proliferation promotion, it is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating joint pain. The egg yolk protein hydrolyzate is a natural-origin material with high safety and, therefore, can be widely used in foods and drinks, medicines, feeds and the like which can be daily ingested.

IPC Classes  ?

• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A23L 33/18 - PeptidesProtein hydrolysates

Goods & Services

(1) (a) Gamma-aminobutyric acid (GABA) for use as a food additive; fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive; (b) dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid and gelled form. (2) Gamma-aminobutyric acid (GABA) used as an ingredient of soft drinks, sports drinks, and smoothies.

Abstract

Provided is a novel active ingredient that can be safely used in preventing, ameliorating or treating cartilage-related diseases such as cartilage injuries or cartilage disorders. An egg yolk protein hydrolysate, which has an effect of promoting cartilage cell growth, is useful as an active ingredient for preventing, ameliorating or treating cartilage disorders and for preventing, ameliorating or treating arthralgia. The egg yolk protein hydrolysate is a natural-origin material with high safety and, therefore, is widely usable in foods, drinks, medicines, feeds and the like that can be daily ingested.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A23L 1/305 - Amino acids, peptides or proteins 
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed are: a novel peptide having an osteoblast proliferation promotion activity; a medicinal agent for promoting the formation of bones, which comprises the peptide; and an excellent use application which utilizes the peptide.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• C07K 5/08 - Tripeptides
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/465 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from birds
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided are an antibody which is effective in inhibiting the formation of a biofilm and removing the same and has a high effect against periodontal bacteria; and an anti-periodontal disease composition which contains said antibody. A chicken egg antibody, which is obtained from an avian egg having been immunized with an antigen that is a culture obtained by mixed-culturing two or more kinds of periodontal bacteria, is used as an anti-periodontal disease composition. The periodontal bacteria preferably comprise two or more kinds of bacteria selected from among Porphyromonas gingivalis, Fusobacterium nucleatum, Actinobacillus actinomycetemcomitans, Tannerella forsythensis, Treponema denticola, Prevotella intermedia and Streptococcus gordonii.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 31/04 - Antibacterial agents
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• C07K 16/02 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from eggs

Abstract

An antistress composition of the invention contains ᜼-aminobutyric acid and a nucleic acid-related compound as active ingredients and it preferably contains ᜼-aminobutyric acid and the nucleic acid-related compound in a mass ratio of 1:0.0001 to 1:0.1. The nucleic acid-related compound is preferably at least one type selected from the group consisting of uracil, uridine, uridylic acid (UMP), uridine 5’-diphosphate (UDP), uridine 5’-triphosphate (UTP), adenine, adenosine, adenylic acid (AMP), adenosine 5’-diphosphate (ADP), adenosine 5’-triphosphate (ATP), inosine, inosinic acid (IMP), inosine 5’-diphosphate (IDP), inosine 5’-triphosphate (ITP), deoxyuridine, deoxyuridylic acid (dUMP), deoxyuridine 5’-diphosphate (dUDP), deoxyuridine 5’-triphosphate (dUTP), deoxyadenosine, deoxyadenylic acid (dAMP), deoxyadenosine 5’-diphosphate (dADP), deoxyadenosine 5’-triphosphate (dATP), deoxyinosine, deoxyinosinic acid (dIMP), deoxyinosine 5’-diphosphate (dIDP), deoxyinosine 5’-triphosphate (dITP), xanthin and salts thereof. The antistress composition of the invention efficiently suppresses/decreases mental fatigue by oral intake, can be expected to have an effect of preventing/improving health disorder caused by the mental fatigue and can be easily formulated into various foods and drinks.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;

Goods & Services

Gamma-aminobutyric acid (GABA) for use as a food additive; fermentation extract, namely, gamma-aminobutyric acid (GABA) by lactic acid bacteria for use as a food additive Dietary and nutritional supplements, all consisting mainly of amino acid in tablet, capsule, granular, powder, liquid, and gelled form

Goods & Services

Gamma-aminobutyric acid (GABA) used as an ingredient of soft drinks, sport drinks, and smoothies